4 results
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
The aim of this study is to evaluate the effect of a single oral dose of TW001 on oxidative stress and pharmacokinetics with and without food. Dosing with an oral solution is considered to have major advantages over iv dosing in a chronic condition…
The primary objective of this clinical trial is to demonstrate the superior efficacy of bococizumab compared with placebo in reducing the risk of major CV events, a composite endpoint which includes adjudicated and confirmed CV death, non fatal MI (…
To evaluate the long-term safety of FAB122 in patients with ALS.